SARS-CoV-2 vaccination in the immunocompromised host - 05/07/22
Doi : 10.1016/j.jaci.2022.05.001
Caoilfhionn M. Connolly, MD, MSc, Julie J. Paik, MD, MHS ⁎ 
Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md
∗Corresponding author: Julie J. Paik, MD, MHS, Johns Hopkins University School of Medicine, 5200 Eastern Ave, MFL Building, Center Tower Suite 4500, Baltimore, MD 21224.Johns Hopkins University School of Medicine5200 Eastern AveMFL BuildingCenter Tower Suite 4500BaltimoreMD21224
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Key words : COVID-19, SARS-CoV-2, vaccination, immunocompromised, antibody response
Il testo completo di questo articolo è disponibile in PDF.
Mappa
| Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant K23AR073927 [to J.J.P.]). |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2022
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 150 - N° 1
P. 56-58 - Luglio 2022 Ritorno al numero
Articolo precedente
- News Beyond Our Pages
- Marc E. Rothenberg, Jean Bousquet
- Can asthma biologics change the course of disease and induce drug-free remission?
- Lauren Cohn
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.